česky english polski

FAQs

I am interested in tests of Myriad company for detection of hereditary dispositions to cancer. Can you tell me where I can ask for this examination?

We recommend contacting the nearest genetics laboratory or your general practitioner. This service can also be provided by oncologic outpatients’ departments.

I was surprised that test results are delivered by Myriad company within 3 weeks. Is it really the case? The other laboratories state the delivery time of several months.

Yes, as a routine, Myriad company is able to analyse your sample within 3 weeks. The analysis is performed in the Munich laboratory, in some examinations, such as Endopredict test, it is possible to analyse the sample locally without cross-border cooperation. The sample is sent abroad by the laboratory or outpatients’ department which took it.

It is not always easy to decide for tests of this type with regard to their price, in spite of the fact that I know that due to occurrence of an oncologic disease among my relatives it would be good for me to be interested in them and thus to eliminate a risk of a possible disease in this way by means of early prevention. Can you explain to me why I should choose the tests of Myriad company?

Myriad has been engaged in this field for more than 20 years and has diagnosed a huge number of patients, more than 1 million. This enabled Myriad to build its own huge resource database of described concrete genetic and phenotype profiles. Together with excellent analytics, bibliography and a team of specialists, Myriad generates maximum clinical action results, i.e. results which will help your doctor to determine the direction of medical care for you or your relatives. Moreover, the results are available in a very short time, within 3 weeks. Nowadays, many laboratories which provide similar services like Myriad also have analytical processes of high standard. A problem may occur when assessing the genetic variants found and their correct classification, as the available public databases which the laboratories usually have to use do not have to provide sufficient information for correct assessment. An important parameter when assessing quality of a laboratory is thus a percentage of so-called variants of unclear importance. The lower this percentage, the higher quality the provided diagnostics has and your doctor will obtain minimum clinical non-action results. As regards breast carcinoma, Myriad guarantees and also documents a percentage of variants of unclear importance up to 2.2 % (0.6 % BRCA1, 1.6 % BRCA2), many other laboratories can be at the level of around 25 %.

I have read that Myriad offers a test which contributes to assessment of tumour aggressiveness in case of a diagnosed prostate carcinoma. Can I find this test in our country? Do I have to have another sample taken if I want to have this examination done?

The test is called Prolaris. It is a genetic test which analyses the activity of genes, cells in the sampled prostatic tissue, in other words the test measures how fast the cells divide in your tumour. It is an independent prognostic marker which can help your urologist and you, together with the other clinic and pathological indicators, to choose the most suitable therapeutic strategy. A tumour always has very individual features. Therefore as regards for example a low risk tumour, you can decide with your doctor to postpone the therapy and an operation and you can choose so-called active surveillance, i.e. a periodical intensive tumour monitoring. On the other hand, if the Prolaris determines that it is a high-risk tumour, more aggressive forms of therapy can be chosen. The laboratory analyses a sample which has already been taken during biopsy or during an operation, therefore it is not necessary to take a new sample unless it is required by a particular situation. You can ask your urologist to perform the test. Nowadays, monitoring of the activity of specific genes plays more and more important role in diagnostics of many diseases.

Is Endopredict test recommended also for women who were diagnosed using a different test in the past in order to choose a suitable therapy?

Yes, with regard to the fact that Endopredict test is capable of diagnosing a risk of not only early but also late metastases, i.e. for a period of 5 to 10 years, an ER+/HER2 negative woman with a primary breast carcinoma can be tested using this test e.g. after a five-year period of the endocrine therapy. By means of the Endopredict test, the doctor will gain information whether it is necessary to continue the endocrine therapy or whether the five-year treatment seems to be sufficient.

In our family there have been various types of tumours in the past, also breast tumours and tumours of large intestine. I have found out about a new test of Myriad company which should be able to assess a risk of several oncologic diseases. Could you please tell me more about it?

It is myRisk test aimed at the most frequent tumour symptoms. It is a unique multi-syndrome testing panel. Among many other genes, it also tests the genes which are used in specifically aimed BracAnalysis or Colaris tests. For an individual with a personal or family oncologic medical history, myRisk test can analyse a risk of several tumour syndrome diseases from one blood sample – i.e. tumours of breast, ovaries, stomach, pancreas, large intestine, uterus, prostate gland and skin. A great benefit of myRisk test is the fact that thanks to aiming at more genes, we can identify significantly more mutations than when using the individual tests specific for a particular tumour.